Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1644 1671
This examiner grants 60% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17417601 | PHAGOCYTISABLE PARTICLE FOR USE IN THE TREATMENT OR PROPHYLAXIS OF CANCER | Final Rejection | NEOGAP THERAPEUTICS AB |
| 17335602 | DIAGNOSTIC BIOMARKERS FOR SHRIMP ALLERGY | Final Rejection | The Chinese University of Hong Kong |
| 18448519 | TEST METHOD AND TEST KIT FOR ADULT STILL'S DISEASE | Non-Final OA | Canon Kabushiki Kaisha |
| 17997298 | COMPOSITIONS AND METHODS OF ADAMTS13 CHIMERIC AUTOANTIBODY RECEPTOR CELLS | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17310262 | METAL CHELATOR COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Final Rejection | Board of Regents, The University of Texas System |
| 17691041 | PREDICTING RESPONSE TO TREATMENTS IN PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA | Final Rejection | Washington University |
| 17557887 | RSV-BASED VIRUS-LIKE PARTICLES AND METHODS OF PRODUCTION AND USE THEREOF | Final Rejection | The Board of Regents for the Oklahoma Agricultural and Mechanical Colleges |
| 17622375 | A PEPTIDE-BASED SCREENING METHOD TO IDENTIFY NEOANTIGENS FOR USE WITH TUMOR INFILTRATING LYMPHOCYTES | Final Rejection | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 16610279 | TARGETED CYTOKINE BLOCKADES FOR CAR-T THERAPY | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18146014 | COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND A DNA-PK INHIBITOR FOR THE TREATMENT OF CANCER | Final Rejection | Pfizer Inc. |
| 17907039 | CORONA NUCLEOCAPSID ANTIGEN FOR USE IN ANTIBODY-IMMUNOASSAYS | Non-Final OA | Roche Diagnostics Operations, Inc. |
| 18620496 | COMPOSITIONS AND METHODS FOR INHIBITION OF LINEAGE SPECIFIC PROTEINS | Non-Final OA | VOR BIOPHARMA INC. |
| 18506518 | ANTIGEN-BINDING PROTEINS TARGETING MELANOMA DIFFERENTIATION ANTIGENS AND USES THEREOF | Non-Final OA | MEMORIAL SLOAN-KETTERING CANCER CENTER |
| 18538698 | ANTI-KIT ANTIBODIES AND USES THEREOF | Final Rejection | Celldex Therapeutics, Inc. |
| 18376678 | METHOD FOR DETECTING DRUG ANTIBODY IN SPECIMEN | Non-Final OA | Shenzhen Blood Center (Shenzhen Institute of Transfusion Medicine) |
| 18282767 | A BISPECIFIC ANTI-PD-L1/VEGF ANTIBODY AND USES THEREOF | Non-Final OA | WUXI BIOLOGICS IRELAND LIMITED |
| 18281094 | Method for Detecting Coronavirus Infection | Non-Final OA | AiSTI SCIENCE Co., Ltd. |
| 18278121 | METHOD FOR SCREENING FUNCTIONAL MATERIAL PALLIATIVE OF ALLERGY, ATOPY, AND ITCHINESS | Non-Final OA | SHEBAH BIOTECH INC. |
| 17059516 | HSP70 PROTEIN LEVELS IN PBMC SAMPLES AS BIOMARKER FOR DISEASE | Non-Final OA | Zevra Denmark A/S |
| 16589914 | Methods of Treating Peripheral T Cell Lymphoma Using Anti-CD30 Antibody Drug Conjugate Therapy | Final Rejection | SEAGEN INC. |
| 18002800 | USES, METHODS AND PRODUCTS RELATING TO OLIGOMERIC LIPOPOLYSACCHARIDE BINDING PROTEINS | Non-Final OA | UNIVERSITETET I OSLO |
| 18026063 | DOWNREGULATION OF MEMBRANE-BOUND PROTEINS BY RECEPTOR TAC TECHNOLOGY | Non-Final OA | Boan Boston LLC |
| 16755590 | ANTI-CD45-BASED LYMPHODEPLETION METHODS AND USES THEREOF IN CONJUNCTION WITH ACT-BASED CANCER THERAPIES | Final Rejection | Actinium Pharmaceuticals, Inc. |
| 18007978 | Compositions and Methods for the Treatment of Synucleinopathies | Non-Final OA | SOLA BIOSCIENCES LLC |
| 17918863 | METHODS FOR TREATING A COMPLEMENT MEDIATED DISORDER CAUSED BY VIRUSES | Non-Final OA | Regis Peffault De Latour |
| 17800472 | 2019-NCOV (SARS-COV-2) VACCINE | Non-Final OA | VAXBIO LTD |
| 17904038 | BIO-THERAPEUTICS FOR DETECTION, DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH MUCOSAL BLEEDING | Non-Final OA | TENZA, INC. |
| 17791711 | PLASMIN-RESISTANT PEPTIDES FOR TREATING STROKE AND RELATED CONDITIONS | Final Rejection | NONO INC. |
| 17490160 | METHOD OF DETERMINING PERCENTAGE OF IMMUNE CELL TYPES IN A SALIVA SPECIMEN | Non-Final OA | Tru Diagnostics, Inc. |
| 17432521 | METHOD FOR THE DIAGNOSIS OF MACCE IN PATIENTS WHO UNDERWENT GASTROINTESTINAL SURGERY | Non-Final OA | Linkoping University Hospital |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy